關(guān)鍵詞:reprocell
簡介：我公司國內(nèi)總代理,華東地區(qū)代理reprocell專業(yè)經(jīng)營進口胎牛血清、細胞因子、ELISA試劑盒、細胞、抗體、生物試劑、耗材、培養(yǎng)基、一抗、二抗、其產(chǎn)品吸附均勻，吸附性好，空白值低，孔底透明度高，代做ELISA實驗等。
國內(nèi)總代理,華東地區(qū)代理reprocell產(chǎn)品涉及分子生物學(xué)、細胞生物學(xué)、細菌學(xué)、遺傳學(xué)、免疫學(xué)、生物化學(xué)、蛋白質(zhì)學(xué)、細胞療、**應(yīng)用等領(lǐng)域。國內(nèi)總代理,華東地區(qū)代理范圍內(nèi)免費運輸，如出現(xiàn)運輸質(zhì)量問題，我們可以包退換貨。reprocell完善的庫存及供應(yīng)體系以及高效穩(wěn)定的磚利純化技術(shù)，保證產(chǎn)品均能現(xiàn)貨供應(yīng)和產(chǎn)品質(zhì)量的穩(wěn)定性。
REPROCELL
About REPROCELL
Overview
Established in 2003 by preeminent Japanese university researchers, REPROCELL quickly became the leading stem cell research company in Japan. Soon thereafter, REPROCELL products were employed by Professor Shinya Yamanaka (Nobel Laureate, 2012) during his pioneering research on induced pluripotent stem cell (iPSC) technologies at Kyoto University. REPROCELL was the first company to offer iPSC-derived human cardiomyocytes, hepatocytes and neuronal cells for research applications. As a market leader, with a portfolio of cells, culture media and reagents, the company was listed on the Japan JASDAQ / Growth stock market in 2013.
In recent years, many commercial opportunities and applications were developed directly upstream and downstream of the iPSC workflow. Therefore, the company aggressively expanded its busines through a series of acquistions to become the REPROCELL Group Companies. Each company it acquired possessed intellectual property and knowledge that helps to amplify the value of the organization by complementing the capabilities of the others. Together, a workflow has emerged that spans from human tissue acquisition (BioServe®, Biopta®), to iPSC reprogramming (Stemgent®), cell differentiation (REPROCELL), in vitro tissue modelling with 3D technology (Reinnervate®), and assay development for applications in drug discovery (Biopta®). More recently, these companies have been integrated and consolidated to regional offices, and the names converted to product and service brands. In the stem cell and drug discovery “market- space”, no other company has this broad combination of expertise that can be applied to nearly the entire span of the drug discovery pipeline, and even to new areas of regenerative medicine. For a concise summary of REPROCELL's overall capabilities.
